---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-025302"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:54:29.237704+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics Q1 net loss narrows to $18.8M; pipeline advances with FHD-909 Phase 1 and degrader programs

## Summary
- Q1 2025 net loss $18.8M vs $25.0M in Q1 2024; collaboration revenue $6.0M (up from $5.1M).
- Cash, equivalents, and marketable securities $220.6M; cash runway into 2027.
- FHD-909 (SMARCA2 inhibitor) Phase 1 dose escalation in SMARCA4-mutated cancers ongoing, NSCLC primary target.
- Selective CBP degrader targeting IND in 2026; ARID1B and EP300 degrader program updates expected H2 2025.
- Board appointments: Neil Gallagher (Syndax President) and Stuart Duty (former Guggenheim Senior MD) in May 2025.

## SEC filing metadata
- accession: 0001628280-25-025302
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025025302/0001628280-25-025302-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025025302/fhtx-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-025302
- JSON: https://secwatch.observer/filing/0001628280-25-025302.json
- Plain text: https://secwatch.observer/filing/0001628280-25-025302.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.